Global Viral Vector and Plasmid DNA Manufacturing Market, 7th Edition: Forecast to 2035 | 9.73% CAGR Unlocks USD 2.16 Billion CMO and Gene Therapy Opportunity
Dublin, Oct. 20, 2026 (GLOBE NEWSWIRE) -- "Viral Vector and Plasmid DNA Manufacturing Market (7th Edition): Industry Trends and Global Forecasts, till 2035" has been added to ResearchAndMarkets.com's offering.
The global viral vector and plasmid DNA manufacturing market is projected to increase from USD 937 million in the current year to USD 2.16 billion by 2035, representing a CAGR of 9.73% during the forecast period. Growth is being supported by the expanding pipeline of cell therapies, gene therapies and vector-based vaccines, alongside rising demand for reliable, scalable and high-quality manufacturing capabilities.
Market Growth and Industry Trends
Viral and non-viral vectors are integral to the development and production of advanced cell and gene therapies. Approximately 30 therapies using viral vectors have received regulatory approval worldwide, while more than 500 candidates are progressing through clinical trials in the US. This expanding pipeline is creating sustained demand for viral vector and plasmid DNA production across preclinical, clinical and commercial scales.
Manufacturers continue to address challenges associated with immunogenicity, process complexity, analytical requirements and production scalability. At the same time, developers are increasing their focus on non-viral vectors, particularly where safety, flexibility and scalable manufacturing are strategic priorities.
Process optimization and manufacturing automation are also improving vector yields and production efficiency. Corning Life Sciences, for example, has introduced high-density cell culture systems, including HYPERStack and CellSTACKs, supported by gas-permeable film technology. Automation platforms are further helping manufacturers reduce manual intervention, streamline workflows and shorten production timelines.
More than 300 industry and non-industry organizations worldwide are supporting the expanding pipeline of vector-based therapies and vaccines. Investments, strategic partnerships and manufacturing facility expansions demonstrate the sector's focus on overcoming capacity constraints and strengthening global supply chains.
Key Market Insights
Market Segmentation and Revenue Outlook
The report analyzes the viral vector and plasmid DNA manufacturing market by scale of operation, application area, vector type, therapeutic area, manufacturer type and geographical region. Operational scales include preclinical, clinical and commercial manufacturing. Applications encompass cell therapies, gene therapies and vaccines, while vector categories include AAV, adenoviral, lentiviral, retroviral, non-viral and other vectors.
The clinical segment currently represents approximately 50% of market revenue, driven by demand from ongoing cell and gene therapy trials. Commercial manufacturing is expected to record a CAGR of 13% through 2035 as more late-stage therapies advance toward regulatory approval and market launch.
Lentiviral vectors hold the largest share by vector type at approximately 25%, supported by multiple lentiviral vector-based cell and gene therapies in late-stage clinical development. AAV vector manufacturing is forecast to expand at a CAGR of 13%, reflecting broader adoption across therapeutic development programs.
Gene therapy applications account for approximately 49% of the market, supported by an increasing number of approved products and clinical candidates requiring high-quality vector production. Manufacturing for cell therapy applications is expected to grow at a CAGR of 11% as clinical pipelines continue to expand.
Oncological disorders currently account for approximately 47% of the market by therapeutic area. Over the long term, vector-based oncology therapies are expected to represent more than 60% of the market. Manufacturing for ophthalmic disorder therapies is projected to record a CAGR of 31%, supported by increasing approvals and pipeline activity involving cell and gene therapies for eye diseases.
Contract Manufacturing and Regional Opportunities
Contract manufacturing organizations currently hold approximately 57% of the market and are projected to expand at a CAGR of 11%. Their ability to provide flexible capacity, specialized expertise and scalable production makes them important partners for therapy developers seeking to manage evolving manufacturing requirements.
North America leads the global market with a 54% share, supported by an established research ecosystem, advanced healthcare infrastructure and substantial installed manufacturing capacity. Asia-Pacific and Middle East and North Africa are each forecast to grow at a CAGR of 11%, driven by increasing investment, expanding biotechnology capabilities and growing demand for advanced treatments addressing genetic, neurological, chronic and rare disorders.
Competitive Landscape
Companies active in the viral vector and plasmid DNA manufacturing market include Advanced BioScience Laboratories, AGC Biologics, Aldevron, Celonic, Catalent Biologics, Charles River Laboratories, Novartis and Oxford BioMedica. Competition is influenced by manufacturing capacity, service portfolios, vector expertise, operational scale, facility location and the ability to support products from early development through commercialization.
The report evaluates company competitiveness, manufacturing capacity, partnerships, facility expansions, emerging vector technologies, pricing considerations and future demand. It also assesses potential strategic partners and factors influencing decisions to retain production in-house or engage a contract manufacturing organization.
Research Scope and Strategic Value
The analysis incorporates primary discussions with executives, scientific leaders, business development professionals, project managers and independent consultants across the US, Europe and Japan. It also examines market drivers, restraints, opportunities and operational challenges affecting viral vector, non-viral vector and plasmid DNA manufacturing.
Stakeholders can use the report to evaluate current and future market size, segment-level revenue opportunities, regional growth prospects, installed capacity and competitive positioning. The findings can support investment planning, partnership development, capacity expansion and go-to-market strategies as demand for vector manufacturing rises through 2035.
Key Topics Covered:
1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Key Questions Answered
1.5. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
5. EXECUTIVE SUMMARY
6. INTRODUCTION
6.1. Chapter Overview
6.2. Viral and Non-Viral Gene Transfer Techniques
6.3. Viral Vectors Used in Genetically Modified Therapies
6.4. Types of Viral Vectors
6.4.1. Adeno-associated Viral Vectors
6.4.1.1. Overview
6.4.1.2. Design and Manufacturing
6.4.1.3. Advantages
6.4.1.4. Limitations
6.4.2. Adenoviral Vectors
6.4.2.1. Overview
6.4.2.2. Design and Manufacturing
6.4.2.3. Advantages
6.4.2.4. Limitations
6.4.3. Lentiviral Vectors
6.4.3.1. Overview
6.4.3.2. Design and Manufacturing
6.4.3.3. Advantages
6.4.3.4. Limitations
6.4.4. Retroviral Vectors
6.4.4.1. Overview
6.4.4.2. Design and Manufacturing
6.4.4.3. Advantages
6.4.4.4. Limitations
6.4.5. Other Viral Vectors
6.4.5.1. Alphavirus
6.4.5.2. Foamy Virus
6.4.5.3. Herpes Simplex Virus
6.4.5.4. Sendai Virus
6.4.5.5. Simian Virus
6.4.5.6. Vaccinia Virus
6.4.5.7. Chimeric Viral Vectors
6.5. Types of Non-Viral Vectors
6.5.1. Plasmid DNA
6.5.2. Liposomes, Lipoplexes and Polyplexes
6.5.3. Oligonucleotides
6.5.4. Other Non-Viral Vectors
6.6. Gene Delivery using Non-Viral Vectors
6.6.1. Biolistic Methods
6.6.2. Electroporation
6.6.3. Receptor Mediated Gene Delivery
6.6.4. Gene Activated Matrix (GAM)
6.7. Applications of Viral and Non-Viral Vectors
6.7.1. Cell and Gene Therapy
6.7.2. Vaccine
6.8. Current / Ongoing Trends in Vector Development / Manufacturing
6.8.1. Vector Engineering
6.8.2. Cargo Engineering
6.9. Vector Manufacturing
6.9.1. Types of Vector Manufacturers
6.9.2. Viral Vector Manufacturing Processes
6.9.2.1. Vector Production
6.9.2.2. Adherent and Suspension Cultures
6.9.2.3. Unit Process Versus Multiple Parallel Processes
6.9.2.4. Cell Culture Systems for Production of Viral Vectors
6.9.2.4.1. Small Scale / Laboratory Scale Cell Culture Systems
6.9.2.4.2. Large Scale Cell Culture Systems
6.9.2.4.2.1. Stirred Tank Reactor Systems
6.9.2.4.2.2. Fixed Bed Reactors / Packed Bed Reactors
6.9.2.4.2.3. Wave Bioreactor Systems
6.9.2.5. Serum-Containing versus Serum-Free Media
6.9.3. Bioprocessing of Viral Vectors
6.9.3.1. AAV Vector Production
6.9.3.2. Adenoviral Vector Production
6.9.3.3. Lentiviral Vector Production
6.9.3.4. ? -Retroviral Vector Production
6.9.4. Key Challenges Associated with Vector Manufacturing
6.10. Future Perspectives
7. VIRAL VECTOR MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Viral Vector and Gene Therapy Manufacturers: Overall Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Type of Product Manufactured
7.2.5. Analysis by Type of Manufacturer
7.2.6. Analysis by Scale of Operation
7.2.7. Analysis by Type of Viral Vector Manufactured
7.2.8. Analysis by Application Area
8. PLASMID DNA MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE
8.1. Chapter Overview
8.2. Plasmid DNA and Gene Therapy Manufacturers: Overall Market Landscape
8.2.1. Analysis by Year of Establishment
8.2.2. Analysis by Company Size
8.2.3. Analysis by Location of Headquarters
8.2.4. Analysis by Type of Company
8.2.5. Analysis by Type of Venture
8.2.6. Analysis by Type of Services Offered
8.2.7. Analysis by Type of Plasmid DNA Manufactured
8.2.8. Analysis by Grade of Plasmid DNA Manufactured
8.2.9. Analysis by Cell Bank
8.2.10. Analysis by Scale of Operation
8.2.11. Analysis by Application Area
8.2.12. Analysis by Viral Vector Used
8.2.13. Analysis by Type of Vaccine Developed
8.2.14. Analysis by Number of Facilities
9. VIRAL VECTOR AND PLASMID DNA MANUFACTURERS (NON-INDUSTRY PLAYERS): MARKET LANDSCAPE
9.1. Chapter Overview
9.2. Viral Vector and Plasmid DNA Manufacturers (Non-Industry Players): Overall Market Landscape
9.2.1. Analysis by Year of Establishment
9.2.2. Analysis by Company Size
9.2.3. Analysis by Location of Headquarters
9.2.4. Analysis by Type of Vector
9.2.5. Analysis by Scale of Operation
9.2.6. Analysis by Type of Manufacturer
9.2.7. Analysis by Application Area
10. VECTOR MANUFACTURING TECHNOLOGIES LANDSCAPE
10.1. Chapter Overview
10.2. Vector Manufacturing Technologies: Overall Market Landscape
10.2.1. Analysis by Type of Technology
10.2.2. Analysis by Purpose of Technology
10.2.3. Analysis by Scale of Operation
10.2.4. Analysis by Type of Vector
10.2.5. Analysis by Application Area
10.2.6. Most Active Players: Analysis by Number of Technologies
11. COMPANY COMPETITIVENESS ANALYSIS
11.1. Chapter Overview
11.2. Methodology and Key Parameters
11.3. Viral Vector Manufacturers: Company Competitiveness Analysis
11.3.1. Players based in North America
11.3.2. Players based in Europe
11.3.3. Players based in Asia-Pacific and Rest of the World
11.4. Plasmid DNA Manufacturers: Company Competitiveness Analysis
11.4.1. Players based in North America
11.4.2. Players based in Europe
11.4.3. Players based in Asia-Pacific and Rest of the World
12. VECTOR MANUFACTURERS BASED IN NORTH AMERICA
12.1. Chapter Overview
12.2. Key Players
12.2.1. Advanced BioScience Laboratories
12.2.1.1. Company Overview
12.2.1.2. Vector Manufacturing Portfolio
12.2.1.3. Recent Developments and Future Outlook
12.2.2. Catalent Biologics
12.2.2.1. Company Overview
12.2.2.2. Financial Information
12.2.2.3. Vector Manufacturing Portfolio
12.2.2.4. Recent Developments and Future Outlook
12.2.3. Charles River Laboratories
12.2.3.1. Company Overview
12.2.3.2. Financial Information
12.2.3.3. Vector Manufacturing Portfolio
12.2.3.4. Recent Developments and Future Outlook
12.2.4. Thermo Fisher Scientific
12.2.4.1. Company Overview
12.2.4.2. Financial Information
12.2.4.3. Vector Manufacturing Portfolio
12.2.4.4. Recent Development and Future Outlook
12.2.5. VectorBuilder
12.2.5.1. Company Overview
12.2.5.2. Financial Information
12.2.5.3. Vector Manufacturing Portfolio
12.2.5.4. Recent Developments and Future Outlook
12.3. Other Key Players
12.3.1. AGC Biologics
12.3.1.1. Company Overview
12.3.1.2. Vector Manufacturing Portfolio
12.3.2. Aldevron
12.3.2.1. Company Overview
12.3.2.2. Vector Manufacturing Portfolio
12.3.3. Matica Biotechnology
12.3.3.1. Company Overview
12.3.3.2. Vector Manufacturing Portfolio
12.3.4. Resilience
12.3.4.1. Company Overview
12.3.4.2. Vector Manufacturing Portfolio
13. VECTOR MANUFACTURERS BASED IN EUROPE
13.1. Chapter Overview
13.2. Key Players
13.2.1. Lonza
13.2.1.1. Company Overview
13.2.1.2. Financial Information
13.2.1.3. Vector Manufacturing Portfolio
13.2.1.4. Recent Developments and Future Outlook
13.2.2. Touchlight
13.2.2.1. Company Overview
13.2.2.2. Vector Manufacturing Portfolio
13.2.2.3. Recent Developments and Future Outlook
13.3. Other Key Players
13.3.1. BioNTech Innovative Manufacturing Service (a subsidiary of BioNTech)
13.3.1.1. Company Overview
13.3.1.2. Vector Manufacturing Portfolio
13.3.2. Biovian
13.3.2.1. Company Overview
13.3.2.2. Vector Manufacturing Portfolio
13.3.3. Celonic
13.3.3.1. Company Overview
13.3.3.2. Vector Manufacturing Portfolio
13.3.4. Centre for Process Innovation
13.3.4.1. Company Overview
13.3.4.2. Vector Manufacturing Portfolio
13.3.5. CEVEC Pharmaceuticals
13.3.5.1. Company Overview
13.3.5.2. Vector Manufacturing Portfolio
13.3.6. NorthX Biologics
13.3.6.1. Company Overview
13.3.6.2. Vector Manufacturing Portfolio
13.3.7. Novartis
13.3.7.1. Company Overview
13.3.7.2. Vector Manufacturing Portfolio
13.3.8. Oxford BioMedica
13.3.8.1. Company Overview
13.3.8.2. Vector Manufacturing Portfolio
13.3.9. Sanofi
13.3.9.1. Company Overview
13.3.9.2. Vector Manufacturing Portfolio
14. VECTOR MANUFACTURERS IN ASIA-PACIFIC
14.1. Chapter Overview
14.2. Key Players
14.2.1. CoJourney
14.2.1.1. Company Overview
14.2.1.2. Vector Manufacturing Portfolio
14.2.1.3. Recent Developments and Future Outlook
14.2.2. Esco Aster
14.2.2.1. Company Overview
14.2.2.2. Vector Manufacturing Portfolio
14.2.2.3. Recent Developments and Future Outlook
14.2.3. Wuxi AppTec
14.2.3.1. Company Overview
14.2.3.2. Financial Information
14.2.3.3. Vector Manufacturing Portfolio
14.2.3.4. Recent Developments and Future Outlook
14.3. Other Key Players
14.3.1. Altruist Biotechnology
14.3.1.1. Company Overview
14.3.1.2. Vector Manufacturing Portfolio
14.3.2. Jiangsu Puxin Biopharmaceutical
14.3.2.1. Company Overview
14.3.2.2. Vector Manufacturing Portfolio
14.3.3. Nikon CeLL innovation
14.3.3.1. Company Overview
14.3.3.2. Vector Manufacturing Portfolio
15. PORTER'S FIVE FORCES ANALYSIS
15.1. Chapter Overview
15.2. Methodology and Assumptions
15.3. Key Parameters
15.3.1. Threats of New Entrants
15.3.2. Bargaining Power of Suppliers
15.3.3. Bargaining Power of Buyers
15.3.4. Threats of Substitute Products
15.3.5. Rivalry Among Existing Competitors
15.4. Concluding Remarks
16. PARTNERSHIPS AND COLLABORATIONS
16.1. Chapter Overview
16.2. Partnership Models
16.3. Vector Manufacturing: Partnerships and Collaborations
16.3.1. Analysis by Year of Partnership
16.3.2. Analysis by Type of Partnership
16.3.3. Analysis by Scale of Operation
16.3.4. Analysis by Type of Vector Manufactured
16.3.5. Analysis by Therapeutic Area
16.3.6. Analysis by Application Area
16.3.7. Most Active Players: Analysis by Number of Partnerships
16.3.8. Analysis by Geography
16.3.8.1. Local and International Agreements
16.3.8.2. Intercontinental and Intracontinental Agreements
17. RECENT EXPANSIONS
17.1. Chapter Overview
17.2. Type of Expansions
17.3. Vector Manufacturing: Recent Expansions
17.3.1. Analysis by Year of Expansion
17.3.2. Analysis by Type of Expansion
17.3.3. Analysis by Year and Type of Expansion
17.3.4. Most Active Players: Analysis by Number of Expansions
17.3.5. Most Active Players: Analysis by Amount Invested
17.3.6. Analysis by Type of Manufacturing Facility
17.3.7. Analysis by Scale of Operation
17.3.8. Analysis by Type of Vector Manufactured
17.3.9. Analysis by Application Area
17.3.10. Analysis by Geography
17.3.10.1. Intercontinental and Intracontinental Expansions
17.3.10.2. Analysis by Location of Expansion
18. STRATEGIC PARTNER ANALYSIS
18.1. Chapter Overview
18.2. Methodology and Key Parameters
18.3. Strategic Partner Analysis: Viral Vector based Therapy Developers
18.3.1. Opportunity for AAV Vector based Therapy Developers
18.3.1.1. Most Likely Partners
18.3.1.2. Likely Partners
18.3.1.3. Less Likely Partners
18.3.1.4. Least Likely Partners
18.3.2. Opportunity for Adenoviral Vector based Therapy Developers
18.3.2.1. Most Likely Partners
18.3.2.2. Likely Partners
18.3.2.3. Less Likely Partners
18.3.2.4. Least Likely Partners
18.3.3. Opportunity for Lentiviral Vector based Therapy Developers
18.3.3.1. Most Likely Partners
18.3.3.2. Likely Partners
18.3.3.3. Less Likely Partners
18.3.3.4. Least Likely Partners
18.3.4. Opportunity for Retroviral Vector based Therapy Developers
18.3.4.1. Most Likely Partners
18.3.4.2. Likely Partners
18.3.4.3. Less Likely Partners
18.3.4.4. Least Likely Partners
18.3.5. Opportunity for Other Viral Vector based Therapy Developers
18.3.5.1. Most Likely Partners
18.3.5.2. Likely Partners
18.3.5.3. Less Likely Partners
18.3.5.4. Least Likely Partners
19. EMERGING VECTORS
19.1. Chapter Overview
19.1.1. Alphavirus based Vectors
19.1.2. Anc80 based Vectors
19.1.3. Bifidobacterium longum based Vectors
19.1.4. Cytomegalovirus based Vectors
19.1.5. Listeria monocytogenes based Vectors
19.1.6. Minicircle DNA based Vectors
19.1.7. Myxoma Virus based Vectors
19.1.8. Self-Complementary Vectors
19.1.9. Sendai Virus based Vectors
19.1.10. Sleeping Beauty Transposons
19.1.11. Vaccinia Virus and Modified Vaccinia Ankara based Vectors
19.1.12. Chimeric Viral Vectors
20. KEY INSIGHTS
20.1. Chapter Overview
20.2. Vector and Gene Therapy Manufacturers: Key Insights
20.2.1. Analysis by Type of Manufacturer, Type of Vector Manufactured and Scale of Operation
20.2.2. Analysis by Type of Vector Manufactured and Company Size
20.2.3. Analysis by Type of Organization and Geography
20.2.3.1. Contract Manufacturing Organizations
20.2.3.2. In-House Manufacturers
20.2.3.3. In-House and Contract Manufacturing Organizations
20.2.4. Analysis by Type of Vector Manufactured and Location of Headquarters
20.2.4.1. AAV Vector Manufacturers
20.2.4.2. Adenoviral Vector Manufacturers
20.2.4.3. Lentiviral Vector Manufacturers
20.2.4.4. Retroviral Vector Manufacturers
20.2.4.5. Plasmid DNA Manufacturers
21. COST PRICE ANALYSIS
21.1. Chapter Overview
21.2. Factors Contributing to High Price of Viral Vector and Plasmid DNA based Therapies
21.3. Viral Vector and Plasmid DNA based Therapies: Pricing Models
21.3.1. Pricing Models Based on Expert Opinions
21.3.2. Pricing Models Based on Manufacturing Cost
21.3.2.1. Pricing Models Based on Technology Used
21.3.2.2. Pricing Models Based on Scale of Operation
21.3.2.3. Pricing Models Based on Type of Client
21.3.3. Prices of Different Types of Vectors
21.4. Concluding Remarks
22. OUTSOURCING: GO / NO-GO FRAMEWORK
22.1. Chapter Overview
22.2. Outsourcing: Go / No-Go Framework
22.3. Vector Manufacturing Outsourcing: Go / No-Go Framework
22.3.1. Key Parameters and Assumptions
22.3.2. Methodology
22.3.3. Results and Interpretations
22.3.3.1. Outsourcing: Go / No-Go Framework for Small Companies
22.3.3.2. Outsourcing: Go / No-Go Framework for Mid-Sized Companies
22.3.3.3. Outsourcing: Go / No-Go Framework for Large Companies
23. CAPACITY ANALYSIS
23.1. Chapter Overview
23.2. Methodology and Key Assumptions
23.3. Viral Vector and Plasmid DNA Manufacturing: Global Installed Capacity
23.4. Viral Vector Manufacturing: Global Installed Capacity
23.4.1. Analysis by Company Size
23.4.2. Analysis by Scale of Operation
23.4.3. Analysis by Location of Headquarters (Region)
23.4.4. Analysis by Location of Manufacturing Facility
23.5. Plasmid DNA Manufacturing: Global Installed Capacity
23.5.1. Analysis by Company Size
23.5.2. Analysis by Scale of Operation
23.5.3. Analysis by Location of Headquarters (Region)
23.5.4. Analysis by Location of Manufacturing Facility
24. DEMAND ANALYSIS
24.1. Chapter Overview
24.2. Assumptions and Methodology
24.3. Global Demand for Viral Vectors and Plasmid DNA, Till 2035
24.4. Global Clinical Demand for Viral Vectors and Plasmid DNA, Till 2035
24.4.1. Analysis by Type of Vector
24.4.2. Analysis by Type of Therapy
24.4.3. Analysis by Therapeutic Area
24.4.4. Analysis by Geography
24.5. Global Commercial Demand for Viral Vectors and Plasmid DNA, Till 2035
24.5.1. Analysis by Type of Vector
24.5.2. Analysis by Type of Therapy
24.5.3. Analysis by Therapeutic Area
24.5.4. Analysis by Geography
24.6. Demand and Supply Analysis
25. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
25.1. Chapter Overview
25.2. Market Drivers
25.3. Market Restraints
25.4. Market Opportunities
25.5. Market Challenges
26. GLOBAL VECTOR MANUFACTURING MARKET
26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Global Vector Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.3.1. Scenario Analysis
26.3.1.1. Conservative Scenario
26.3.1.2. Optimistic Scenario
26.4. Key Market Segmentations
27. VECTOR MANUFACTURING MARKET, BY SCALE OF OPERATION
27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. Vector Manufacturing Market: Distribution by Scale of Operation
27.3.1. Preclinical Scale: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
27.3.2. Clinical Scale: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
27.3.3. Commercial Scale: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
27.4. Data Triangulation and Validation
28. VECTOR MANUFACTURING MARKET, BY TYPE OF VECTOR MANUFACTURED
28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Vector Manufacturing Market: Distribution by Type of Vector
28.3.1. AAV Vectors: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
28.3.2. Adenoviral Vectors: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
28.3.3. Lentiviral Vectors: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
28.3.4. Retroviral Vectors: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
28.3.5. Non-Viral Vectors: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
28.3.6. Other Vectors: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
28.4. Data Triangulation and Validation
29. VECTOR MANUFACTURING MARKET, BY APPLICATION AREA
29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. Vector Manufacturing Market: Distribution by Application Area
29.3.1. Cell Therapy: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
29.3.2. Gene Therapy: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
29.3.3. Vaccines: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
29.4. Data Triangulation and Validation
30. VECTOR MANUFACTURING MARKET, BY THERAPEUTIC AREA
30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Vector Manufacturing Market: Distribution by Therapeutic Area
30.3.1. Oncological Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.3.2. Rare Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.3.3. Immunological Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.3.4. Neurological Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.3.5. Sensory Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.3.6. Metabolic Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.3.7. Blood Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.3.8. Musculoskeletal Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.3.9. Infectious Diseases: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.3.10. Ophthalmic Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.3.11. Other Disorders: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.4. Data Triangulation and Validation
31. VECTOR MANUFACTURING MARKET, BY TYPE OF MANUFACTURER
31.1. Chapter Overview
31.2. Key Assumptions and Methodology
31.3. Vector Manufacturing Market: Distribution by Type of Manufacturer
31.3.1. In-house Manufacturers: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
31.3.2. Contract Manufacturing Organizations: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
31.4. Data Triangulation and Validation
32. VECTOR MANUFACTURING MARKET, BY GEOGRAPHICAL REGION
32.1. Chapter Overview
32.2. Key Assumptions and Methodology
32.3. Vector Manufacturing Market: Distribution by Geographical Region
32.3.1. North America: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
32.3.2. Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
32.3.3. Asia-Pacific: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
32.3.4. Middle East and North Africa: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
32.3.5. Latin America and Rest of the World: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
32.4. Data Triangulation and Validation
33. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA
33.1. Vector Manufacturing Market in North America: Distribution by Scale of Operation
33.1.1. Vector Manufacturing Market in North America for Preclinical, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.1.2. Vector Manufacturing Market in North America for Clinical, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.1.3. Vector Manufacturing Market in North America for Commercial, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.2. Vector Manufacturing Market in North America: Distribution by Type of Vector Manufactured
33.2.1. Vector Manufacturing Market in North America for AAV Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.2.2. Vector Manufacturing Market in North America for Adenoviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.2.3. Vector Manufacturing Market in North America for Lentiviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.2.4. Vector Manufacturing Market in North America for Retroviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.2.5. Vector Manufacturing Market in North America for Non-Viral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.2.6. Vector Manufacturing Market in North America for Other Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.3. Vector Manufacturing Market in North America: Distribution by Application Area
33.3.1. Vector Manufacturing Market in North America for Cell Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.3.2. Vector Manufacturing Market in North America for Gene Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.3.3. Vector Manufacturing Market in North America for Vaccines, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.4. Vector Manufacturing Market in North America: Distribution by Therapeutic Area
33.4.1. Vector Manufacturing Market in North America for Oncological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.4.2. Vector Manufacturing Market in North America for Rare Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.4.3. Vector Manufacturing Market in North America for Immunological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.4.4. Vector Manufacturing Market in North America for Neurological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.4.5. Vector Manufacturing Market in North America for Sensory Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.4.6. Vector Manufacturing Market in North America for Metabolic Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.4.7. Vector Manufacturing Market in North America for Blood Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.4.8. Vector Manufacturing Market in North America for Musculoskeletal Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.4.9. Vector Manufacturing Market in North America for Infectious Diseases, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.4.10. Vector Manufacturing Market in North America for Ophthalmic Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.4.11. Vector Manufacturing Market in North America for Other Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.5. Vector Manufacturing Market in North America: Distribution by Type of Manufacturer
33.5.1. Vector Manufacturing Market in North America for In-house Manufacturer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
33.5.2. Vector Manufacturing Market in North America for Contract Manufacturers, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
34. MARKET OPPORTUNITY ANALYSIS: EUROPE
34.1. Vector Manufacturing Market in Europe: Distribution by Scale of Operation
34.1.1. Vector Manufacturing Market in Europe for Preclinical, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
34.1.2. Vector Manufacturing Market in Europe for Clinical, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
34.1.3. Vector Manufacturing Market in Europe for Commercial, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
34.2. Vector Manufacturing Market in Europe: Distribution by Type of Vector Manufactured
34.2.1. Vector Manufacturing Market in Europe for AAV Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
34.2.2. Vector Manufacturing Market in Europe for Adenoviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
34.2.3. Vector Manufacturing Market in Europe for Lentiviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
34.2.4. Vector Manufacturing Market in Europe for Retroviral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
34.2.5. Vector Manufacturing Market in Europe for Non-Viral Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
34.2.6. Vector Manufacturing Market in Europe for Other Vectors, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
34.3. Vector Manufacturing Market in Europe: Distribution by Application Area
34.3.1. Vector Manufacturing Market in Europe for Cell Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
34.3.2. Vector Manufacturing Market in Europe for Gene Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
34.3.3. Vector Manufacturing Market in Europe for Vaccines, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
34.4. Vector Manufacturing Market in Europe: Distribution by Therapeutic Area
34.4.1. Vector Manufacturing Market in Europe for Oncological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
34.4.2. Vector Manufacturing Market in Europe for Rare Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
34.4.3. Vector Manufacturing Market in Europe for Immunological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
34.4.4. Vector Manufacturing Market in Europe for Neurological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
34.4.5. Vector Manufacturing Market in Europe for Sensory Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
34.4.6. Vector Manufacturing Market in Europe for Metabolic Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
34.4.7. Vector Manufacturing Market in Europe for Blood Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
34.4.8. Vector Manufacturing Market in Europe for Musculoskeletal Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
34.4.9. Vector Manufacturing Market in Europe for Infectious Diseases, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
34.4.10. Vector Manufacturing Market in Europe for Ophthalmic Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
34.4.11. Vector Manufacturing Market in Europe for Other Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
34.5. Vector Manufacturing Market in Europe: Distribution by Type of Manufacturer
34.5.1. Vector Manufacturing Market in Europe for In-house Manufacturer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
34.5.2. Vector Manufacturing Market in Europe for Contract Manufacturers, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
35. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC
35.1. Vector Manufacturing Market in Asia-Pacific: Distribution by Scale of Operation
A selection of companies mentioned in this report includes, but is not limited to:
For more information about this report visit https://www.researchandmarkets.com/r/ebpxj5
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.